stockrow
Friday 6 November 2026
Export NKGN’s income statement to Excel — free account
NKGen Biotech, Inc.
NKGN Healthcare Biotechnology
NKGen Biotech, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $77,000.00.
- EPS
- +232.0%
- Free cash flow
- +28.7%
Quarter to March 2025, against a year earlier
0.01
0.00
0.00%
Follow NKGN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM Mar ’25 | Trend | 10 yrs | 2025e | 2026e | 2027e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | 76.62 | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (1) | (27) | (83) | (44) | (24) | +254.8% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | (34,736.36) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | 0 | — | — | — | (1) | (27) | (83) | (44) | (24) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (0.06) | (4.21) | (5.38) | (1.54) | (1.06) | +198.8% | ||||||
| Cash flow | — | — | — | — | — | — | (0.10) | (3.55) | (1.42) | (0.72) | (0.43) | +92.8% | ||||||
| Capex | — | — | — | — | — | — | 0.00 | (0.03) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | (0.10) | (3.57) | (1.43) | (0.72) | (0.43) | +92.9% | ||||||
| Book value | — | — | — | — | — | — | (0.72) | 0.25 | (3.80) | (2.42) | (1.10) | +49.7% | ||||||
| Shares, m | — | — | — | — | — | — | 15 | 6 | 15 | 29 | 32 | +24.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | 40.46 | — | — | 0.00 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | (3.32) | — | — | (1.52) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (2) | (23) | (22) | (21) | (20) | +139.3% | |||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | (71.8%) | ||||||
| Free cash flow | — | — | — | — | — | — | (2) | (23) | (22) | (21) | (20) | +139.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 1 | (14) | (38) | (56) | (42) | n/m | |||||
| Net debt | — | — | — | — | — | — | (2) | 12 | 10 | 43 | 30 | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (11) | 2 | (59) | (70) | (50) | +85.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | (1.14) | (28.09) | (505.65) | (270.76) | (146.49) | (269.6) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | (116.15) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 573.40 | 290.40 | 68.87 | 44.70 | +68.9 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 6 | 4 | 63 | 26 | — | +63.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.02 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022 · latest quarter Dec 2022 · fundamentals updated 26 Oct 2026
NKGen Biotech, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AEON AEON Biopharma, Inc. | $9.4M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | Compare |
| PHIO Phio Pharmaceuticals Corp. | $9.3M | — (loss-making) | — (loss-making) | −8.70% (below 0%: shrinking) | n/m | −58.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MBRX Moleculin Biotech, Inc. | $9.2M | 0.0× | — | — | n/m | −19.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CURX Curanex Pharmaceuticals Inc | $9.1M | — (loss-making) | — | — | n/m | −272.32% (below 0%: shrinking) | — | 0.00% | Compare |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | $9.1M | — (loss-making) | — | — | n/m | +47.89% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CALC CalciMedica Inc. | $8.9M | — (loss-making) | — | — | n/m | +31.42% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BLRX BioLineRx Ltd. | $8.8M | — (loss-making) | — (loss-making) | −3.29% (below 0%: shrinking) | n/m | −1,827.71% (below 0%: shrinking) | 79.93% | (1,215.31%) | Compare |
| LEXX Lexaria Bioscience Corp. | $8.8M | — (loss-making) | — (loss-making) | −89.12% (below 0%: shrinking) | n/m | +53.90% (above 0%: growing) | 100.00% | 0.00% | Compare |
| NKGN NKGen Biotech, Inc. | $8.8M | — (loss-making) | — | — | n/m | +28.68% (above 0%: growing) | 100.00% | 0.00% | |
| Median of peers | $9.1M | — | — | −8.70% | — | −38.96% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 3 February 2025
Ownership
Directors and executive officers, together
10.36%
NKMAX Co., Ltd.
26.01%
BDW Investments LLC
11.21%
CFIC-2015 NV Family Investments, LLC
8.86%
Meteora Entities
8.10%
Graf Acquisition Partners IV LLC
7.26%
James A. Graf
6.92%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement